Effect of tumor necrosis factor-a blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease

Inflammatory Bowel Diseases

Volumn 19, Issue 2, 2013, Pages 259-264

  Biancheri, Paolo ^a,b   Di Sabatino, Antonio ^b   Rovedatti, Laura ^b   Giuffrida, Paolo ^b   Calarota, Sandra A ^b   Vetrano, Stefania ^c   Vidali, Francesca ^b   Pasini, Alessandra ^b   Danese, Silvio ^c   Corazza, Gino R ^b   MacDonald, Thomas T ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Adalimumab; Gut homing; Inflammatory bowel disease; Infliximab; Integrin

Indexed keywords

ADALIMUMAB; BETA1 INTEGRIN; IMMUNOGLOBULIN G1; INFLIXIMAB; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; CONTROLLED STUDY; CROHN DISEASE; DOWN REGULATION; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; BLOTTING, WESTERN; COLON; CROHN DISEASE; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULINS; INTEGRIN BETA CHAINS; MALE; MIDDLE AGED; MUCOPROTEINS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84876348570     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31828100a4     Document Type: Article

References (27)

1. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272:60-66.
2. Gorfu G, Rivera-Nieves J, Ley K. Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med. 2009;9:836-850.
3. Berlin C, Berg EL, Briskin MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 1993;74:185-195.
4. Salmi M, Jalkanen S. Molecules controlling lymphocyte migration to the gut. Gut. 1999;45:148-153.
5. Streeter PR, Berg EL, Rouse BT, et al. A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature. 1988;331;41-46.
6. Nakache M, Berg EL, Streeter PR, et al. The mucosal vascular addressin is a tissue-specific endothelial cell adhesion molecule for circulating lymphocytes. Nature. 1989;337:179-181.
7. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151:97-110.
8. Di Sabatino A, Rovedatti L, Rosado MM, et al. Increased expression of mucosal addressin cell adhesion molecule 1 in the duodenum of patients with active celiac disease is associated with depletion of integrin alpha4- beta7-positive T cells in blood. Hum Pathol. 2009;40:699-704.
9. Arihiro S, Ohtani H, Suzuki M, et al. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Pathol Int. 2002;52:367-374.
10. Souza HS, Elia CC, Spencer J, et al. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut. 1999;45:856-863.
11. Di Sabatino A, Biancheri P, Rovedatti L, et al. New pathogenic paradigms in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:368-371.
12. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000;51:289-298.
13. Sikorski EE, Hallmann R, Berg EL, et al. The Peyer's patch high endothelial receptor for lymphocytes, the mucosal vascular addressin, is induced on a murine endothelial cell line by tumor necrosis factor-alpha and IL-1. J Immunol. 1993;151:5239-5250.
14. Oshima T, Pavlick KP, Laroux FS, et al. Regulation and distribution of MAdCAM-1 in endothelial cells in vitro. Am J Physiol Cell Physiol. 2001; 281:C1096-C1105.
15. Ogawa H, Binion DG, Heidemann J, et al. Mechanisms of MAdCAM-1 gene expression in human intestinal microvascular endothelial cells. Am J Physiol Cell Physiol. 2005;288:C272-C281.
16. Connor EM, Eppihimer MJ, Morise Z, et al. Expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in acute and chronic inflammation. J Leukoc Biol. 1999;65:349-355.
17. Danese S, Sans M, Scaldaferri F, et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol. 2006;76:2617-2624.
18. Arijs I, De Hertogh G, Machiels K, et al. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol. 2011;106:748-761.
19. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
20. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Gut. 1989;30:983-989.
21. Di Sabatino A, Pender SL, Jackson CL, et al. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology. 2007;133:137-149.
22. Viney JL, Jones S, Chiu HH, et al. Mucosal addressin cell adhesion molecule-1: a structural and functional analysis demarcates the integrin binding motif. J Immunol. 1996;157:2488-2497.
23. Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, et al. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:373-379.
24. Xia L, Lu J, Xiao W. Blockage of TNF-a by infliximab reduces CCL2 and CCR2 levels in patients with rheumatoid arthritis. J Investig Med. 2011; 59:961-963.
25. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001;11:372-377.
26. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353: 1912-1925.
27. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008;6:1370-1377.